TB-500 and thymosin β4: repair is a cytoskeletal programme

If you've not met thymosin β4 by its day job, here's the molecule: a forty-three-residue, intrinsically disordered peptide — floppy, no fixed fold — acetylated at the amino-terminal serine in the native protein, mass about 4.96 kilodaltons, and the principal G-actin sequestering peptide of animal cells. That last clause is the job. Actin monomers, G-actin, are 42-kilodalton proteins that polymerise into filaments, F-actin, and those filaments are how a cell pushes a membrane, grips a matrix, and divides. Left unbuffered, a cytoplasm full of G-actin would polymerise wherever a barbed end presented itself. Thymosin β4 binds the monomer one-to-one and holds it off the filament until profilin, a local drop in occupancy, or a nucleating machine asks for it. Daniel Safer showed in 1991 that the abundant actin-sequestering peptide Fx and thymosin β4 were the same molecule. Allan Goldstein had isolated the thymosins from thymus two decades earlier as putative immune hormones. The cytoskeletal identification is the one that survived contact with biochemistry, and it is the one this page is about.

In short. Thymosin β4 is a small, floppy protein that holds spare actin so a cell can crawl when it needs to — and that holding job is the whole story here.

TB-500 is a laboratory analogue built around that actin-holding idea, and it isn't automatically a synonym for the forty-three-mer. Research material sold under the trade name has been, depending on the certificate, a motif peptide orbiting LKKTETQ, a longer fragment, or, when the supplier is honest and the synthesis is the expensive one, the full Tβ4 chain. The catalogue listing is 10 mg, lyophilised, ≥98% by HPLC, CAS 885340-08-9, molecular weight reported in the neighbourhood of 4.9 kilodaltons for the full-length analogue, sequence named as the LKKTETQ motif / Tβ4 analogue. Those lines are the ligand. A nickname on a cap isn't. We stock the characterised analogue so a scratch assay, a pyrene-actin curve, or a G/F-actin spin can name what went into the well, rather than guessing after the gap has closed. Identity is a mass spectrum — the machine that weighs the chain. Repair, if the word is allowed at all, is a cytoskeletal programme that starts with that mass.

In short. TB-500 is a lab copy built around the actin-holding idea, not automatically the full natural protein, so read the label or you don't know what you added.

When we say repair in the lab, we don't mean a feeling. It's a named tissue, a named insult, a named readout, and a clock. Re-epithelialisation of an alkali-burned cornea. Endothelial migration across a scratch in eight hours. A G/F-actin ratio by centrifugation. Pyrene-labelled actin polymerising in a cuvette. Hydroxyproline in a fibrotic heart. Those are assays. Healing is the word we reach for when we don't yet want to name the assay. Cells crawl by parking and releasing actin monomers. Thymosin β4 is the buffer. Injury spills it; VEGF, matrix metalloproteinases and keratinocyte migration follow on the extracellular papers. Cardiac and corneal models that moved a phenotype used full-length Tβ4 — Goldstein, Smart, Bock-Marquette, Sosne. Ac-SDKP, the N-terminal tetrapeptide, is a separate anti-fibrotic fragment. BPC-157 is a different molecule entirely, a gastric 15-mer with a VEGFR2 story. This page is the actin programme, the named papers, and why a 10 mg cake of a characterised analogue is a reagent rather than a protocol.

In short. Repair in a lab is a named test: a cut in a dish, an eye injury in a rodent, a measurement of free versus filament actin — not a brochure word.

Three pharmacophores hide under one thymosin conversation, and the first job is telling them apart. Full-length Tβ4 is the 43-mer, the G-actin sponge, the ligand the cardiac and corneal papers actually weighed. LKKTETQ, residues 17–23, is the principal actin-binding motif; the core hexapeptide LKKTET is the stretch mutagenesis papers usually cut. Ac-SDKP is N-acetyl-seryl-aspartyl-lysyl-proline, snipped from the amino terminus by prolyl oligopeptidase, anti-fibrotic, not an actin sequesterer. TB-500, as a trade name, has been used for more than one of those chains. HPLC-MS is how you know which you reconstituted. A certificate without a mass is a label. A label isn't a ligand. We'll walk what the named sequences actually do: Goldstein’s isolation, Safer’s identification, Huff’s review, the treadmill that Pollard and Borisy made a textbook cycle, the injury-release literature, the heart and the cornea, the tetrapeptide that isn't the motif, and the gastric 15-mer that folklore glued to this analogue without a shared receptor. No dosing. The papers already ran the models.

In short. Three different pieces of the thymosin story get sold under similar names: the full protein, the actin-grabbing motif, and a four-residue anti-scarring fragment.

Write the forty-three-mer and you can already see the chemistry. Native thymosin β4 is acetylated at serine 1, acidic, a pI around 5, no disulfide, no fold a crystallographer would take home. Theoretical mass for Ac-Tβ4 is 4963.5 daltons. Intrinsically disordered proteins bind by capturing a partner rather than by presenting a pre-formed pocket, and Tβ4:G-actin is a textbook case. The actin monomer is a nucleotide-binding protein with a pointed and a barbed end conceptually borrowed from the filament. Tβ4 occupies a surface that blocks both ends of the monomer from joining a filament, which is what sequestration means. The Kd sits in the micromolar range, matched to the cellular concentration of the peptide, which is also micromolar in many cytoplasms. That matching is the biology. A buffer only works if the buffer and the ligand are present at comparable concentrations. Picomolar Tβ4 in a well, against millimolar actin in a cell you just lysed, isn't a sequestration experiment. It's a misunderstanding of scale.

In short. The full protein is small, floppy, and abundant inside cells, one copy per spare actin molecule, so a tiny dose in a dish isn't the same physics.

LKKTETQ is residues 17–23 of thymosin β4, the principal actin-binding motif identified by peptide-mapping and mutagenesis in the 1990s. Van Troys, Vandekerckhove, Ampe, and the Hannappel and Safer laboratories did the biochemistry: the motif is necessary for G-actin sequestration; surrounding residues tune affinity; the N-terminal Ac-SDKP is a different pharmacophore entirely. A heptapeptide isn't a 43-mer. It doesn't carry the nuclear-localisation-adjacent story some Tβ4 papers tell, it doesn't carry the same extracellular signalling literature, and it doesn't generate Ac-SDKP when a prolyl oligopeptidase bites the amino terminus, because it has no such terminus. Treating motif, fragment, and full-length protein as one healing peptide is how three pharmacophores become a single nickname. A blot can't tell them apart if you never ran the mass. A scratch assay can't tell them apart if you never ran a G-actin binding measurement. Name the chain. Then crawl.

In short. Seven amino acids in the middle of thymosin β4 grab spare actin, and that piece isn't the whole protein or the separate anti-scarring fragment.

The analogue on a research shelf exists because full-length Tβ4 is a more expensive synthesis, a more demanding characterisation, and a molecule whose clinical-adjacent neighbours — the RegeneRx RGN programmes — already occupy a different regulatory and commercial world. A motif-centred analogue lets a migration assay ask whether the actin-binding idea is sufficient for a given phenotype in a dish. Sometimes it will be. Sometimes the phenotype that Sosne saw on a cornea, or that Bock-Marquette saw in a heart, needed the rest of the 43-mer, or needed Ac-SDKP, or needed a cell type that releases endogenous Tβ4 when you injure it and doesn't care what you pipetted. Those are empirical questions. They're the reason you characterise the peptide first and run the assay second. The other order — run the scratch, get a closed gap, then ask the supplier what was in the vial — is how posters get written, and how two labs that think they replicated each other discover, a year later, that they used different chains.

In short. Labs use a shorter analogue because it's simpler to make, and some effects of the full protein may need the rest of the chain — that's an experiment.

Sequence is identity, and identity is the first experiment. The lyophilised cake on a certificate will also report trifluoroacetate or acetate counter-ions depending on the cleavage and the salt exchange, and a careful experiment writes which. Purity ≥98% HPLC is a peak, not a physiology. A deletion peptide missing one lysine can hide under a cheap ultraviolet trace and still wreck a sequestration assay, which is why the interesting chromatogram is the one with a mass on it, not the one with a pretty single peak at 214 nanometres. We put the sequence and the mass on the certificate. We don't put a healing percentage on it, because a healing percentage isn't a property of an analogue. It's a property of a model, a dose, a clock, and a control group someone else already ran. Confirm the reconstituted stock the morning you seed the well. Lyophilised peptides are hygroscopic, labels smudge, and the tube you think is the analogue is, in a crowded freezer, sometimes the other tube.

In short. A peptide is its amino-acid sequence and its mass, so a lab document should show both; a pretty peak alone isn't enough, and tubes get mixed.

Allan Goldstein isolated the thymosins from calf thymus in the 1960s and 1970s as putative immune hormones — a family of small acidic peptides of which thymosin α1 and thymosin β4 became the famous ones, and we still live with that first job title. The immune-hormone frame was the frame of that decade: thymus as an endocrine gland, peptides as the secretions, immunity as the endpoint. Some of that frame survived. Thymosin α1 went on to a clinical life of its own. Thymosin β4’s ageing was more interesting. The protein is abundant in almost every cell, not just in thymocytes; it is one of the most plentiful peptides in a platelet; and the job that survived contact with biochemistry wasn't a hormone receptor. It was actin. Goldstein kept publishing, including later work on endothelial migration and on the peptide as a repair factor, and those papers sit downstream of the cytoskeletal identification rather than instead of it. Isolation is history. Identification is the plot twist. A nickname is neither.

In short. Thymosin β4 was first pulled from the thymus and treated as an immune hormone, then turned out to be a common cell protein whose real job is holding spare actin.

Daniel Safer, Marilyn Elzinga and Vivian Nachmias, Journal of Biological Chemistry 1991, is the paper we'd cite if we were starting the conversation at the bench. They showed that thymosin β4 and Fx, the actin-sequestering peptide already on the blot in platelet and other extracts, were the same chain. The identification retired a decade of split literature in a single biochemical sentence. You can still run the experiment they ran, with modern mass spectrometry instead of Edman chemistry, and you'll get the same answer: the abundant small acidic peptide that holds G-actin is Tβ4. Subsequent work mapped the contact, measured the Kd, and placed the peptide in the same neighbourhood as profilin, cofilin and the barbed-end polymerases. A thymic hormone had been a monomer sponge. That's one of the better demotions in peptide history, because the molecule didn't get smaller. The job got sharper. Anyone still writing Tβ4 as an unspecified healing factor hasn't sat with Safer’s title.

In short. In 1991 a biochemistry paper showed that the famous thymic peptide and the cell's known actin-holding peptide were the same molecule.

Huff, Müller, Otto, Netzker and Hannappel wrote the review we'd keep on the bench: β-thymosins, small acidic peptides with multiple functions, International Journal of Biochemistry and Cell Biology, 2001. Intrinsically disordered. One-to-one with G-actin. A reservoir that profilin, cofilin and the barbed-end polymerases draw on when a lamellipodium is required. Expression high in platelets, macrophages, wound fluid. Release from dying or activated cells as an extracellular signal that, in later papers, moves VEGF, MMPs and keratinocyte migration. The extracellular chapter is how a G-actin buffer became a repair literature. Inside the cell it is a monomer sponge. Outside, it is a peptide other cells can see. Those are two jobs, and they don't have to share a receptor. The intracellular job is binding actin. The extracellular job is still being mapped, and some of it may be the N-terminal tetrapeptide after a protease cut, which is already a third job. Huff’s review is the document. Goldstein’s isolation is the history. Safer’s identification is the plot twist.

In short. Actin biologists treat this protein as a monomer sponge inside the cell, and outside it can also act as a signal — two jobs that may use different pieces.

Concentration is the variable most captions skip, and it's the variable that decides whether you've a buffer or a guess. Tβ4 in a resting platelet or a neutrophil cytoplasm isn't a picomolar hormone. It's a micromolar partner of a micromolar pool of G-actin. Cell Biology by the Numbers, and the older cytoskeletal surveys, put the peptide in that range because a stoichiometric sponge has to be there in copy numbers that match the monomer. A growth factor such as VEGF-A works at picomolar-to-nanomolar occupancy of a receptor tyrosine kinase. Those regimes don't overlap, and they should not be written as if they did. Extracellular Tβ4, once released, may be closer to a cue, and the VEGF-induction papers sit there, at nanomolar-to-micromolar doses in medium, which is already a different physics from the intracellular buffer. A motif analogue at an arbitrary microgram-per-millilitre in a well isn't automatically either regime. Dose, medium, cell type, and a G-actin binding measurement are how you find out which regime you're in.

In short. Inside a cell this protein is abundant spare parts, not a rare hormone, and outside after injury it may act more like a cue, at a different dose.

The demotion from hormone to buffer is also a lesson about how peptide literatures age. Goldstein wasn't wrong to pull small acidic peptides out of thymus; the gland is full of them, and thymosin α1 earned a separate clinical life. He was working with the tools and the endocrine language of his decade. Safer was working with actin biochemistry, pyrene traces, and a peptide that refused to behave like a ligand at a seven-helix receptor. Both programmes published. The one that still organises an experiment is the cytoskeletal one, because you can measure sequestration in a cuvette without a story about the immune system. Immune effects of extracellular Tβ4 exist in later papers — inflammatory tone, leukocyte migration, a wound-fluid neighbourhood — and they're allowed to exist without dragging the molecule back into an unspecified hormone slot. Name the assay. If it is G-actin binding, you're in Safer’s room. If it is a cytokine panel, you're in another room. The peptide can visit both. The caption can't flatten them.

In short. First it was called a thymic hormone, then an actin buffer; both literatures exist, so the useful move is to name the measurement.

Mutational mapping put the actin contact on a short stretch in the middle of the chain. Van Troys and colleagues, working through substitutions and fragments, showed that the hexapeptide LKKTET — leucine-lysine-lysine-threonine-glutamate-threonine, residues 17–22 — is necessary for G-actin sequestration, with glutamine 23 completing the LKKTETQ motif that research analogues usually name. Surrounding residues tune on-rate and off-rate. The amino-terminal cluster, including the Ac-SDKP tetrapeptide, can be altered without destroying sequestration; the motif cannot. That's what ‘principal actin-binding motif’ means. It doesn't mean a heptapeptide is a drop-in replacement for a 43-mer in every assay. It means that if you want to know whether a phenotype needs the grip on G-actin, you break this stretch, or you use a chain that never had it, and you ask whether the pyrene curve and the crawl both move. A motif-only analogue is half of that experiment. A motif-disrupted 43-mer is the other half. Most wells run neither. They run a scratch and a photograph.

In short. A stretch in the middle of the chain is what grabs actin — break that stretch, or use a chain that never had it, if you want to know whether the crawl needed the grip.

Structurally, sequestration is a steric sentence. G-actin has two faces that join a filament: the barbed-end face and the pointed-end face. Tβ4 drapes across the monomer so that neither face is free to dock. Profilin binds a different surface and, unlike Tβ4, delivers the monomer to barbed ends rather than hiding it. The exchange between Tβ4-actin and profilin-actin is how a cell keeps a large sequestered pool and still feeds a lamellipodium on demand. Cofilin severs aged, ADP-actin filaments and feeds monomers back into the pool. Arp2/3 nucleates branches off existing filaments, the dendritic array of a lamellipodium. Formins nucleate unbranched cables. None of those machines is the peptide. The peptide is the clerk who decides how many monomers are free to join. If we write TB-500 as a growth factor, we've skipped the clerk and invented a motor. The motor is actin. The analogue, at best, is one of the clerks.

In short. The protein covers the joining faces of an actin building block so it cannot enter a filament, and other proteins then hand the block to the growing front.

Affinity is micromolar because the biology is stoichiometric. A nanomolar Kd would lock monomers so tightly that profilin could not recover them on the timescale of a protrusion. A millimolar Kd wouldn't hold a useful reserve. Evolution parked the number in the window where the peptide is a buffer, not a trap and not a spectator. That's why an experiment that dumps an analogue into a well at an unmeasured microgram-per-millilitre, against an unknown serum actin and an unknown extracellular protease landscape, isn't yet doing sequestration. It's doing a phenotype. Phenotypes are allowed. They aren't Kd. DNase I inhibition, pyrene-actin polymerisation, a pull-down with biotin-actin, a G/F ratio after a 100,000 g spin: those assays were old when TB-500 got its trade name. They still work. Running a scratch without them is how you generate a closed gap you can't attribute. Running them without HPLC-MS is how you attribute a phenotype to the wrong chain.

In short. The grip is medium-strength on purpose, so spare actin can be held and then released — a closed gap in a dish doesn't prove that grip happened.

A motif analogue is a tool with a stated limit. It can ask whether LKKTETQ-shaped chemistry is sufficient for a given readout in a given cell. It can't ask whether the rest of the 43-mer is required, because the rest isn't there. Nuclear localisation, some of the extracellular signalling, the generation of Ac-SDKP, the particular surface that Bock-Marquette tied to integrin-linked kinase in a cardiac explant: those are 43-mer questions. If your cardiac study wants Srivastava’s molecule, synthesise or buy the acetylated 43-mer, confirm the mass, and write Tβ4 in the methods. If your fibroblast scratch wants the actin-binding idea, the analogue is a lawful reagent, provided the certificate and the pyrene curve agree. The experiment write-up is where you pick. Pretending the pick has already been made by a trade name is how three pharmacophores collapse into one caption, and how a catalogue that kept them distinguishable would be wasting the only interesting thing a catalogue can do.

In short. A short analogue can test the actin-grabbing idea, but it can't stand in for the whole protein in heart or eye papers that used the forty-three-residue chain.

Actin treadmilling is the physics of a crawl, and we should slow down for it. Monomers add to the barbed, plus, end of a filament and leave from the pointed, minus, end. In a lamellipodium the barbed ends face the membrane; polymerisation pushes; cofilin and tropomyosin and myosin help the rear keep up; adhesion complexes grip so the push becomes locomotion rather than blebbing. Pollard, Borisy, Theriot, and a generation of reconstituted motility papers made this a textbook cycle. Thymosin β4’s place in the cycle is the reservoir: a pool of G-actin that isn't free to add to barbed ends until a GEF, a profilin exchange, or a local drop in Tβ4 occupancy releases it. Profilin-actin is the form the barbed end actually wants. The peptide doesn't replace any of those machines. It holds the spare parts. A cell that can't sequester G-actin has a noisy, poorly timed polymerisation. A cell that can't release G-actin can't push. The buffer is interesting because injury, and a handful of extracellular cues, change how much of it is available, and where.

In short. Cells crawl by adding actin building blocks at the front of a filament and taking them off at the back, and thymosin β4 holds the spare blocks until the front needs them.

Lamellipodia are the broad, sheet-like protrusions of a migrating cell; filopodia are the spikes. Both are actin. A keratocyte on a coverslip, the classic fish-scale crawler, is a lamellipodium with a nucleus riding behind. A fibroblast closing a scratch throws both structures, messily, and a keratinocyte sheet closing a corneal defect is a collective crawl with junctions still half-on. A scratch assay scores, crudely, whether those protrusions closed a gap. A more honest assay scores protrusion rate, focal-adhesion turnover, and the G/F-actin ratio by centrifugation or by a fluorescent reporter. Tβ4 shifts that ratio toward G. A motif analogue should do the same if it sequesters, and should fail to do the same if the well contains a chain that never bound actin. That's the biochemical distinction this page keeps promising: not an antibody against a brand name, an activity. The order is identity, activity, then the prettier picture of cells crawling into a gap. Reverse the order and you'll photograph something. You won't know what it was.

In short. The broad ruffles at the front of a moving cell are actin sheets — watch them close a gap, or better, measure whether the peptide grabbed actin first.

We should name the other clerks, because it's easy to skip them. Profilin binds G-actin and nucleotide, suppresses spontaneous nucleation, and hands monomers to barbed ends and to formins. Cofilin binds aged ADP-F-actin, severs, and raises the off-rate at pointed ends; too much cofilin dismantles the array, too little lets it freeze. Arp2/3, activated by WAVE and WASP-family proteins at the membrane, nucleates a branch at about seventy degrees, which is the geometry of a lamellipodium’s dendritic mesh. Formins, including mDia, processively add monomers to unbranched filaments, the cables of a filopodium and of a contractile bundle. Capping protein stops barbed-end growth so the array stays short and branched. Thymosin β4 sits upstream of all of that as a sequestered reserve. A page that names only Tβ4 and a closed scratch hasn't described a crawl. It has described a gap. The machines are the crawl. The analogue is, at most, a perturbation of the reserve those machines draw on.

In short. Other named proteins build, branch, cut and cap the actin mesh, and thymosin β4 is the spare-parts store those machines draw from, not the mesh itself.

The G/F-actin ratio is the measurement that earns the word sequestration. Homogenise, spin at a force that pellets filaments, assay actin in supernatant versus pellet, or use a commercial kit built on the same idea. Live-cell reporters — LifeAct, SiR-actin, G-actin-specific probes — give you a picture rather than a pellet, with the usual caveats that the probe is itself an actin-binding peptide. Pyrene-actin is the cuvette version: a cysteine-labelled monomer whose fluorescence jumps on polymerisation, a curve you can shift with a sequesterer, a nucleator, or a capping protein. DNase I binds G-actin tightly and its inhibition is an old G-actin assay. None of these is glamorous. All of them are how you stop a repair write-up becoming a photograph of a gap that was going to close anyway. If the analogue doesn't move a G/F ratio or a pyrene curve, and still closes a scratch, you've an extracellular-cue phenotype, or a serum artefact, or a detergent. Write that. It's a better paper than a forced cytoskeletal caption.

In short. The honest test is whether free actin rose and filament actin fell; if a gap still closes without that shift, the peptide was doing something else.

We shouldn't call a buffer a motor, and it isn't a growth factor. Myosin is a motor: ATP, a lever arm, a filament to walk on. VEGF is a growth factor: a ligand, a receptor tyrosine kinase, a transcriptional and a migratory programme, a concentration a cell is built to notice at picomolar-to-nanomolar occupancy. Tβ4 inside a cell is a stoichiometric partner of actin. Those three objects don't share a dose, a receptor, or a second-messenger cascade, and they should not share a sentence except to keep them apart. Extracellular Tβ4 may induce VEGF, which is a neighbouring claim and a named one, Malinda and Goldstein and Kleinman, and that induction is how a cytoskeletal buffer sits in an angiogenesis paragraph without being VEGF. Distinguishing ‘the cell crawls because its actin is being told to’ from ‘the cell crawls because a peptide in the medium is being read as a cue’ is the point of a G-actin binding mutant. Those mutants exist in the literature. They're the experiment a motif-only analogue is half-way toward, and also the experiment a motif-only analogue can't finish.

In short. A growth factor is a rare signal a cell is built to notice, a motor walks on filaments, and the actin-holding protein is abundant spare parts.

Platelets dump their contents into a wound; macrophages arrive; damaged cells leak. We should start there. Thymosin β4 is abundant in those compartments, so injury is, among other things, an extracellular Tβ4 pulse. Huff’s review already named wound fluid. Subsequent papers treated the released peptide as a cue: endothelial cells migrate toward it, keratinocytes migrate, VEGF expression rises, MMP-2 rises, inflammatory tone modulates. That's how a G-actin buffer became a repair literature without ceasing to be a G-actin buffer. Inside the surviving cell the sponge still holds monomers. Outside, the same sequence is a peptide other cells can see. Two addresses, two concentration regimes, possibly two fragments after a protease has been at the amino terminus. An experiment that adds analogue to a medium and harvests a closed scratch has done an extracellular experiment, unless it has shown otherwise. An experiment that loads a cell and measures G/F has done the intracellular one. Write which. The injury literature mixed them for years, and some of the mix was earned, because a wound bed is both a crawl and a cue.

In short. When tissue is damaged, this protein spills out of platelets and broken cells, and other cells then migrate toward it — an outside job related to, but not the same as, holding actin inside.

Malinda, Goldstein and Kleinman, FASEB Journal 1997, showed directional migration of human umbilical-vein endothelial cells toward thymosin β4. That paper is why an actin-buffer peptide sits in an angiogenesis paragraph without being VEGF. The assay is a Boyden chamber or a similar gradient, a counted crawl, a concentration, a cell type that is foetal, venous and proliferative, which you should say. Directional migration isn't the same as a scratch. A scratch is a sheet closing a gap it made itself; a chamber is a choice between wells. Both appear in the Tβ4 literature. Only the chamber, plus a VEGF ELISA or a VEGFR2 inhibitor, starts to tell you whether the peptide is a cue that induces a growth factor or a cytoskeletal perturbation that makes the same cell more willing to crawl. Often both are a little true. Writing only one of them is how a neighbourhood becomes a single word. We keep them as two measurements. HUVECs are still the workhorse if you say so. They aren't a tendon capillary and not an adult artery.

In short. A 1997 paper showed blood-vessel cells crawling toward this peptide, which is a cue experiment, not proof that the peptide is the famous vessel-growth factor itself.

Matrix metalloproteinases are the extracellular-matrix scissors, and MMP-2 is the isoform the Tβ4 papers name most often. A crawling cell that can't nick collagen IV and the gel around it will push against a wall. A crawling cell that nicks too much will dissolve the track it needed. Induction of MMP-2 by extracellular Tβ4 is therefore a lawful repair-adjacent claim, and also a lawful tumour-adjacent claim, which is why the same peptide turns up in both literatures and why neither literature gets to own the molecule. Zymography on a gelatin gel, an antibody, a TIMP blot, and a broad MMP inhibitor on the next well are the tools. If the analogue raises MMP-2 and a protease inhibitor reopens the scratch, you've a matrix story. If MMP-2 moves and the scratch does not, you've a zymogram. If the scratch closes and MMP-2 doesn't move, you were never in this paragraph. Keratinocyte papers sit next door: a sheet of epithelium that must crawl, a basement membrane that must be remade, a clock a histologist can score. Those papers used full-length Tβ4 more often than a motif analogue. Write the chain.

In short. Cells that crawl through tissue also cut the surrounding mesh, and this peptide has been reported to raise one of those cutting enzymes — measure the enzyme, then see if blocking it undoes the crawl.

Keratinocyte migration is the skin and cornea half of the same extracellular sentence. A wound in stratified epithelium closes by a sheet of keratinocytes that loosens junctions, throws lamellipodia, and reconstitutes a barrier. Tβ4 has been reported to send those cells migrating, to modulate inflammatory cytokines in the bed, and, in Sosne’s alkali-burned cornea, to speed re-epithelialisation while damping the inflammatory score. The eye is a fair organ for a migration peptide: a sheet that must crawl, a stroma that must not scar into opacity, a clinical endpoint a slit lamp can see. Skin punch-biopsy models are dirtier and more familiar. In both cases the honest chain, historically, was the 43-mer. A motif analogue in a keratinocyte scratch is a lawful question about sufficiency, not a retrospective substitution into Sosne’s methods. Collectives crawl differently from single fibroblasts. Cadherins, a wound-edge leader population, a trailing sheet: if your assay can't see those, you're scoring a gap, not an epithelium. Either is science. Only one is Sosne’s neighbourhood.

In short. Skin and corneal surface cells close a wound as a sheet, and eye-injury papers used the full protein, so a short analogue in a dish is a different, still useful, question.

VEGF induction is the sentence that tempts people to file Tβ4 as an angiogenic growth factor, and the filing is a category error even when the induction is real. Vascular endothelial growth factor-A is a ligand for VEGFR2, a receptor tyrosine kinase; occupancy phosphorylates the kinase, internalises the receptor, and runs Akt, eNOS, PLCγ, a programme this catalogue already named in the BPC-157 piece. Tβ4 isn't that ligand. Reports that extracellular Tβ4 raises VEGF expression in endothelial or wound-associated cells are reports of a transcriptional or translational consequence, one or two doors downstream of whatever the peptide occupied or perturbed. The experiment that follows isn't a testimonial. It is: does a VEGF-blocking antibody, or SU5416, take the endothelial crawl with it? If yes, you were looking at a VEGF-dependent cue. If no, you were looking at something else, possibly the cytoskeletal reserve in the same cell. Both answers are publishable. If we stop at ‘TB-500 is angiogenic’, we've skipped the antibody, the chain, and the door.

In short. Some papers say this peptide makes cells produce a vessel-growth factor, which doesn't make the peptide itself that factor — block the factor and see whether the crawl dies.

Cardiac repair is the paper that took Tβ4 out of the wound-fluid literature and put it on a Nature page, and we should read it at the size it actually is. Bock-Marquette, Saxena, White, Dimaio and Srivastava, Nature 2004: thymosin β4 activates integrin-linked kinase, promotes cardiac cell migration and survival, and, in a coronary-ligation model, improves survival and reduces scarring. Integrin-linked kinase is another focal-adhesion neighbourhood protein, which is how a cytoskeletal buffer and a heart-injury phenotype can share a sentence without sharing BPC-157’s VEGFR2. Subsequent cardiac papers argued about pinocytosis, about epicardial progenitors, about whether the effect was on existing cardiomyocytes or on a repair population. The argument is what a Nature paper is for. Full-length Tβ4 is the ligand those experiments used. A motif analogue in a lyophilised cake isn't automatically that ligand. If your cardiac explant study wants Srivastava’s molecule, confirm the 43-mer and write Tβ4 in the write-up. If it wants the actin-binding idea in a fibroblast scratch, the analogue is a lawful tool. The experiment write-up is where you pick.

In short. A 2004 Nature paper used the full protein in a heart-injury model and named a different adhesion kinase — that experiment used the forty-three-amino-acid chain, not a short analogue.

Iain Smart, Paul Riley and colleagues, Nature 2007, took the cardiac story into the epicardium, and we need that chapter too. Thymosin β4 induced adult epicardial progenitor mobilisation and neovascularisation: a sheet of cells on the heart’s surface that, in the embryo, seeds coronary vessels and, in the adult, is mostly quiet until a cue asks it to move again. Tβ4, in their hands, was such a cue. Epicardium isn't myocardium. Progenitor mobilisation isn't cardiomyocyte division. Neovascularisation isn't a G/F-actin pellet. All three can be true in one animal without being one mechanism, and the 2007 paper is the reason a Tβ4 cardiac paragraph that only cites 2004 is unfinished. It's also the reason a motif analogue can't be silently substituted into a progenitor-outgrowth protocol. Riley’s group used characterised full-length peptide. So did Bock-Marquette. So, as a rule, did the laboratories that tried to replicate, qualify, or argue with those figures. Goldstein’s name sits on the endothelial-migration ancestor of both papers. Smart’s name sits on the epicardial chapter. Write both. Write the chain.

In short. A 2007 paper showed the full protein can wake a quiet cell layer on the heart's surface and help new vessels form, which is a different job from holding actin inside a fibroblast.

Corneal repair is Sosne's neighbourhood, and it's the cleanest organ-level application of a migration peptide we've got. Alkali injury is a standard ophthalmic insult: a timed burn, a re-epithelialisation clock, an inflammatory score, a scar that decides whether the eye stays clear. Thymosin β4 promoted corneal wound healing and decreased inflammation after alkali injury in vivo — Experimental Eye Research, 2002, and a run of follow-ups. The eye is anatomically almost designed for this assay. A sheet of epithelium must crawl. A stroma must not scar into opacity. A slit lamp can see the endpoint without killing the animal on the first day. Later work from the same neighbourhood put Tβ4 on dry-eye and neurotrophic-keratopathy conversations, which is how a cytoskeletal peptide walked toward a clinic. Those papers used the 43-mer. Citing them as evidence for a motif peptide in a keratinocyte scratch is a category error. Citing them as evidence that actin-buffer biology can reach a tissue a person has is a fair historical sentence. Keep the error and the sentence on different lines.

In short. Eye-injury papers used the full protein on a burned cornea and scored how fast the surface grew back — a neighbour of the analogue, not a substitute for naming the chain in your dish.

Goldstein's later work is the connective tissue between isolation, endothelial crawl, and the repair programmes, and we shouldn't skip it. Having pulled the thymosins from thymus as immune hormones, he spent subsequent decades on Tβ4 as a migration and repair factor, including the Malinda endothelial paper and collaborations that sit next to Sosne and next to the dermal models. That career arc is why popular paragraphs still say ‘thymic peptide’ when they mean ‘G-actin sequesterer that also acts extracellularly’. Both halves can be written without a hormone receptor. The isolation was thymic. The job that aged was cytoskeletal and, once released, a cue. Smart’s epicardial paper and Bock-Marquette’s ILK paper are the cardiac applications of that cue-plus-cytoskeleton object. Sosne is the ocular application. None of those applications is a motif-only analogue until someone runs the analogue in the same model and shows sufficiency. The analogue we stock is for the bench that wants to ask that sufficiency question, with a certificate, not for a caption that borrows a Nature figure and a slit-lamp photograph.

In short. The scientist who first isolated the thymosins later studied this protein as a repair factor; heart and eye papers used the full chain, and the analogue is for asking whether the actin motif is enough.

RegeneRx’s RGN programmes are the clinical-adjacent neighbour, and they have to be written at the size they actually are. RGN-259 was an ophthalmic formulation of full-length Tβ4; RGN-137 was the dermal neighbour. They took characterised 43-mer into human studies. Mixed readouts, not empty ones, and a reminder that the cytoskeletal programme is, in principle, drug-able. Phase 2 is Phase 2. A mixed human readout is information: you can move a mechanism in a rodent and in a dish and still not own a clinical endpoint a regulator will accept. Those programmes used formulated full-length Tβ4, not a research analogue in a 10 mg cake. Citing a Phase 2 ophthalmic study as evidence for a motif peptide in a scratch assay is the same category error as citing Bock-Marquette for a fibroblast G/F spin you haven't run. Citing it as evidence that actin-buffer biology has been asked, in people, with a characterised chain, is the sentence the neighbour earns. We'll keep the neighbour named and the analogue on its own certificate.

In short. Human eye and skin studies used formulated full-length protein, with mixed results — a real attempt, and not the same object as the freeze-dried analogue on a research shelf.

N-acetyl-seryl-aspartyl-lysyl-proline is the amino-terminal tetrapeptide of thymosin β4, generated physiologically by prolyl oligopeptidase. The enzyme cuts after the proline of Ac-SDKP and releases a four-residue peptide that has its own life. Ac-SDKP doesn't carry LKKTETQ. It doesn't sequester G-actin. It's an anti-fibrotic and angiogenesis-modulating fragment with an ACE-adjacent literature: angiotensin-converting enzyme degrades Ac-SDKP, ACE inhibitors raise circulating and tissue levels of the tetrapeptide, and some of the anti-fibrotic benefit of ACE inhibitors has been argued to run through this fragment rather than only through angiotensin II. Carretero’s group spent years on that axis, with hydroxyproline, collagen I, and fibroblast assays as the readouts. Lumping Ac-SDKP with motif-only TB-500 and with 43-amino-acid Tβ4 under one healing-peptide label is how a literature gets garbled. Three pharmacophores, three assays. G-actin binding for the motif. Hydroxyproline and collagen I for the tetrapeptide’s anti-fibrotic claim. The full 43-mer when your model is Sosne’s cornea or Srivastava’s heart.

In short. A four-amino-acid piece snipped from the front of thymosin β4 has its own anti-scarring papers, and it doesn't bind actin, so treat it as a third molecule, not a nickname.

Prolyl oligopeptidase is a serine protease with a taste for short proline-containing peptides, cytosolic in many cells, and not a wound-bed curiosity. If a cell or a fluid has Tβ4 and has this enzyme, Ac-SDKP will appear. That's a biochemical fact, and it is why a 43-mer experiment is never only a 43-mer experiment once proteases are in the medium. Serum, a tissue homogenate, an inflamed cornea, an infarcted ventricle: all of them can snip the amino terminus. A motif analogue that never had that terminus can't generate the tetrapeptide, which is either a virtue or a limitation depending on the question. If you wanted sequestration without the anti-fibrotic fragment, the analogue is cleaner. If you wanted the fragment, buy the tetrapeptide, or use the 43-mer and measure Ac-SDKP. ACE activity, captopril or lisinopril as tools, a mass-spec assay for the tetrapeptide: those are the controls. Pretending a TB-500 cake is a convenient source of Ac-SDKP is how you run an experiment whose active species you never named.

In short. An enzyme in cells can clip the four-residue fragment off the full protein, and a short actin analogue never had that front end, so it can't make the fragment.

Keep the three names on three tubes. Full-length Tβ4 when the paper you're replicating used the 43-mer — Bock-Marquette, Smart, Sosne, Malinda, the RGN formulations. Motif analogue when the question is whether LKKTETQ-shaped chemistry is sufficient for a G/F shift or a crawl in a named cell. Ac-SDKP when the question is fibrosis, ACE-adjacent collagen, a hydroxyproline endpoint. A certificate that can't tell you which of those three you reconstituted has already failed, before any cell was seeded. The catalogue listing is the analogue, sequence and mass declared, 10 mg, HPLC-characterised, the actin-binding idea on a cake. Neighbouring essays on this desk take BPC-157 apart as a gastric 15-mer and take the pair apart as a folklore stack. This page exists so the analogue isn't asked to carry a Nature cardiac figure, a slit-lamp photograph, and a tetrapeptide’s anti-fibrotic claim in a single caption. Three chains. Three certificates, if you're doing the work. One trade name, if you're not.

In short. Use the full protein, the actin motif analogue, or the four-residue fragment according to the question — the lab listing is the analogue, and the other two are different orders.

Body protection compound-157 is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, written GEPPPGKPADDAGLV, mass 1419.5 daltons, a fifteen-residue fragment of a gastric protein, proline-rich, stubborn in acid, studied for three decades as a cytoprotective and angiogenic probe. TB-500 orbits an actin-binding motif of thymosin β4. They got glued into a healing pair because both showed up in injury models and both were short enough to lyophilise. Biochemistry didn't glue them. One talks, on the cleaner papers, to a receptor tyrosine kinase and to focal-adhesion kinase. The other parks actin monomers so a cell can push a lamellipodium. If you can't tell those jobs apart, you're not yet running an experiment. You're repeating a pairing you haven't tested. This catalogue keeps both vials because both literatures are real, and keeps them apart because the literatures aren't one literature. The neighbouring essay on the pair is the joint. This page is the actin half. The gastric half has its own piece.

In short. The stomach peptide people pair with TB-500 is fifteen amino acids from a gut protein, with a vessel-receptor story — it isn't an actin buffer, and they share a rumour, not a job.

VEGFR2 is KDR, Flk-1, a receptor tyrosine kinase. It's not a G-actin binding surface. Seven-helix receptors, G proteins, arrestin, cAMP — that is a different superfamily again, and this catalogue uses it for incretins and ghrelin mimetics and melanocortins. Hsieh, Liu, Wang and colleagues tied BPC-157 to VEGFR2 activation and internalisation in endothelium, with Akt and eNOS downstream. Chang, Tsai, Lin, Hsu and Pang put FAK and paxillin on the tenocyte side. Tβ4’s cardiac neighbourhood is integrin-linked kinase, another adhesion kinase, and its intracellular day job is the monomer sponge. You can put both peptides in a wound-bed sentence because a wound needs a vessel and a crawling cell. You can't put them in a receptor sentence, a mass-spectrum sentence, or a kinase sentence without lying. There is no heterodimer. There is no shared receptor. There is no paper in which a defined molar ratio of GEPPPGKPADDAGLV and LKKTETQ was the independent variable and a named kinase the dependent one. Phenotype rhyme is the weakest reason to co-administer two ligands, and the most common.

In short. The stomach peptide talks to a vessel-growth receptor and a grip kinase, and the actin analogue talks to actin — a wound might need both jobs, which doesn't make them one pathway.

The factorial is the experiment the stack never ran. BPC-157 alone, TB-500 alone, both, neither, on a named readout, with identity confirmed on both cakes. Until that figure exists in a paper you trust, the pairing is a resemblance. A wound bed does need a vessel and a crawling cell; angiogenesis without migration is leaky granulation tissue, and migration without a blood supply is a sheet that dies in the middle. Combining an angiogenic probe with a cytoskeletal probe is, as a hypothesis, the sort of thing a tumour biologist already knows from VEGF plus integrin papers. The hypothesis is lawful. The leap from hypothesis to a fixed pair of research peptides, at borrowed ratios, in the absence of a factorial, isn't. We'll sell the two characterised chains to a laboratory that can name them. We won't write them as a protocol. GHK-Cu sits in an adjacent room with copper and a fibroblast array. KPV sits in a barrier room with PepT1. Neighbourhood, in this journal, is a courtesy on a reading list. It's not a combination claim.

In short. A fair test would use each peptide alone and both together on one measured job; that test is mostly missing, and pairing them in a thread isn't the same as running it.

cAMP is amplified from an occupancy. One occupied Gs-coupled receptor, one cyclase, thousands of cyclic-AMP molecules, protein kinase A, a phosphorylation cascade, a transcriptional programme. That's why a picomolar hormone can run a cell. NAD+ in the neighbouring essay is the opposite of amplification: sirtuins and PARP spend it, one molecule per lysine or per ADP-ribose. Thymosin β4 is closer to the spend than to the cascade. One peptide, one G-actin, a reserve that isn't multiplied by an enzyme. Stoichiometry is the whole trick. Writing a second-messenger diagram next to an actin sequesterer is how you stop borrowing cascade language for a clerk. The analogue doesn't occupy a class-B GPCR and raise cAMP. It doesn't occupy VEGFR2. Reports of downstream VEGF, ILK, or MMP-2 are reports of consequences, sometimes real, that still have to name the first binding event. If the first binding event is G-actin, show the G/F shift. If it is something else, show the something else. A cloud of arrows from a trade name to a wound isn't a pathway.

In short. Hormones often work by making a loud messenger inside the cell, and this peptide works one-for-one with actin, so don't borrow cascade language for a clerk.

Concentration regimes are how you keep the language honest. Picomolar-to-nanomolar is occupancy at a receptor tyrosine kinase or a GPCR. Micromolar-to-hundreds-of-micromolar is a stoichiometric partner of a cytoskeletal pool. Nanomolar-to-micromolar in a medium, after injury, is the grey zone where extracellular Tβ4 may be a cue. An arbitrary microgram-per-millilitre of analogue in a well is none of those until you measure it, convert it, and compare it with the Kd and with the cell’s own Tβ4. People skip that because a closed scratch is prettier than an arithmetic line in a notebook. Prettier isn't a mechanism. The second-messenger diagram earns its keep on this page as a warning label: Akt, eNOS and nitric oxide are an amplification cascade when VEGFR2 is the lock, which is the BPC-157 neighbourhood. ILK is a kinase in the Tβ4 cardiac papers, and kinases amplify, but the intracellular day job of the peptide is still subtraction from the free G-actin pool. Two chemistries can live in one wound. They can't share a caption without a measurement that says which chemistry you're in.

In short. Rare signals and abundant spare parts don't use the same amounts, so convert your dish dose to a real concentration and compare it with how tightly the peptide holds actin.

Identity, then activity, then phenotype. That order is the whole experiment, and we'd hold to it on a shared bench. HPLC-MS of the cake. HPLC-MS of the reconstituted stock. A concentration you actually measured, not a nominal microgram-per-millilitre from a label that assumed the cake was dry and the balance was true. Vehicle matched: acetic acid, TFA residual, bacteriostatic water, whatever you used, in the control wells at the same volume. Serum stated, because serum is ligands and proteases and a VEGF bath. A cell type that has the machinery you claim — a fibroblast or a keratocyte for a G/F shift, HUVECs if you're in Malinda’s neighbourhood, a keratinocyte or corneal epithelial line if you're in Sosne’s, a cardiac explant if you're in Bock-Marquette’s and you've actually bought the 43-mer. Species stated. Then the G-actin assay. Then the inhibitor or the scrambled ligand. Then the thing you actually wanted to photograph. Reverse that order and you'll photograph something. You won't know what it was. Characterise the peptide. Then run the assay. The other order is how you end up with a picture you can't interpret.

In short. First prove what is in the tube, then prove it does the actin chemistry you claim, then take the pretty picture — reverse that order and you only have a picture.

Pyrene-actin polymerisation is the cuvette the field already agreed on. Label cysteine 374, watch fluorescence rise as filaments form, add your ligand at a stated concentration, and ask whether the curve slows as a sequesterer should. DNase I inhibition is the older G-actin measurement. A 100,000 g spin that pellets F and leaves G is the ratio. A biotin-actin pull-down asks whether the chain in the tube actually bound the monomer. Latrunculin, used carefully and titrated, is a cytoskeletal poison that interprets a scratch: if the analogue still closes a gap when polymerisation is already blocked, the analogue wasn't doing polymerisation. A scrambled peptide of the same mass is the negative ligand. Heat-inactivated peptide, if the activity should be sequence-specific. None of that is exotic. All of it is older than the trade name. A Western for Tβ4 can confirm a 43-mer entered a lysate; it won't necessarily see a motif analogue, and it can't confirm sequestration. Mass spectrometry of the medium, before and after the incubation, will tell you whether the chain survived the well. Peptides disappear. Proteases in serum, adsorption to plastic, a pH you didn't measure.

In short. Tube tests that watch actin form filaments, plus a scrambled copy of the chain, are how you show the job, and short peptides also vanish into plastic and enzymes.

A scratch is a low-specificity endpoint, and it will keep being one. Seed a monolayer. Wait until it is confluent. Scratch it with a pipette tip. Image at 0, 8, 12, 24 hours. The gap closes by cells crawling, and, if you let it go too long, by proliferation, which is why a mitomycin C arm exists in a careful protocol. Add the peptide at a stated concentration, from a stock whose identity you've confirmed, in a medium whose serum content you've written down. Put a cytoskeletal control in the next well. Put a VEGF-blocking antibody in the one after that if you're claiming a cue. Put a scrambled analogue in the one after that. If the chain closes the gap and the G/F ratio moves, you've a cytoskeletal paper. If the chain closes the gap and a VEGF antibody reopens it, you've a cue paper. If the chain closes the gap and nothing orthogonal moves, you've a photograph of a gap that fibroblasts close because you fed them, because the density was wrong, or because the pipette tip released a wound signal. The first two are science. the third is only a photograph.

In short. The simple dish test is a scratch in a sheet of cells: time the gap, and run blockers and a scrambled chain beside it, because gaps close for many reasons.

Dose is where folklore does its worst work. In-vitro endothelial papers that named Tβ4 used nanomolar-to-micromolar peptide, which is a lawful range for an extracellular cue and already a different range from the intracellular buffer. Cardiac and corneal papers used their own microgram-range local doses of the 43-mer. Collapsing those into a single human milligram figure is a unit conversion that physics didn't authorise. A research well should start at a log series around the concentrations in the paper you're replicating, and should include a zero and a toxic high. If the phenotype only appears at a concentration that detaches the monolayer, you've a detergent, not a ligand. If it appears at one point on the curve and vanishes on either side, you may have a real pharmacology, and you should be happy, because biphasic curves are how a lot of honest peptide biology looks. Write the curve. Do not pick the point that flattered the hypothesis. Convert micrograms per millilitre to molarity using the mass on the certificate, not the mass you hoped the analogue had.

In short. Papers use very different amounts in a dish and in an animal, so copy the range from the paper you are repeating, include a zero, and convert the dose into a real concentration.

Species, sex, age, and passage aren't footnotes. HUVECs are a foetal, venous, proliferative population. Primary fibroblasts lose phenotype in culture; passage number belongs in the write-up. Corneal epithelium in a dish isn't a tear film. A young male rodent with a ligation or an alkali burn is the animal a lot of the organ papers used. An aged animal, a diabetic animal, a different species, will move the same endpoints differently. None of this is a reason to stop. It's a reason to stop writing as if a fibroblast scratch were a person. The jump from a well to an organism is the jump the clinical Tβ4 programmes actually tried to make, with mixed results. The analogue hasn't made that jump in a literature I'd put next to those programmes. Preclinical is a class of evidence. It's not a small human trial that someone forgot to publish. Blinded scoring of lesion area and of re-epithelialisation, because those endpoints are where hope enters the callipers. A written analysis plan before the first pyrene curve, so that the antibody you added on Friday isn't the one that worked.

In short. Say which cell and which animal you used — a dish of vessel cells isn't a heart, and a rodent eye isn't a human trial.

Controls are the part a careful experiment can still save. Scrambled peptide, same mass, different sequence. Vehicle. A sequesterer you already trust, if the claim is sequestration. A nucleator or a serum spike as the positive crawl, so a dead dish is obvious. Inhibitor arms matched to the claim: latrunculin or a formin inhibitor for the cytoskeletal sentence; a VEGF-blocking antibody or SU5416 for the cue sentence; an ACE inhibitor or a measured Ac-SDKP if you wandered into the tetrapeptide. Pre-registration if you're in a world that offers it. At minimum, a written plan, an n, and the blot or the curve shown rather than a bar that hides it. The analogue will survive contact with a proper control. If it does not, it wasn't what the caption said, and that is a result worth publishing. We'll sell you the named chain. We won't design the blot, and we won't write a protocol that pretends a 10 mg cake is a 43-mer, a tetrapeptide, or a gastric 15-mer. The papers are public. The certificate is on the listing. The assay is yours.

In short. Include a scrambled chain, the liquid without peptide, and a treatment you already know works; if those are missing, the figure is a draft.

The programme is cytoskeletal, which is the only reason a thymic isolation, a platelet extract, a pyrene cuvette, a corneal burn and a coronary ligation can sit in one page without being a collage. Goldstein pulled small acidic peptides out of thymus. Safer showed the abundant one was the G-actin sequesterer. Huff reviewed a disordered 43-mer that binds monomer one-to-one. Pollard and Borisy described the treadmill that spends that reserve. Malinda showed endothelial cells crawl toward the released peptide. Bock-Marquette and Smart put the 43-mer on a heart. Sosne put it on a cornea. Carretero’s neighbourhood took the N-terminal tetrapeptide into fibrosis. Research TB-500 puts the actin-binding motif on a certificate so a scratch assay can name the ligand. Conservation of actin across eukaryotes isn't a licence to treat a mouse cornea as a human protocol. It's a licence to take the biochemistry seriously enough to measure it, in the cell you have, with the chain the paper actually used. The popular story got loud because crawling cells are easy to film. The work got hard because three pharmacophores share a trade name.

In short. From a thymic extract to a heart paper, the useful thread is actin — a rodent eye result isn't automatically a human plan, and a short analogue isn't the full protein.

The public papers are the reading list, and they're short enough to actually read. Safer, Elzinga, Nachmias, Journal of Biological Chemistry 1991, Tβ4 is Fx. Huff, Hannappel, International Journal of Biochemistry and Cell Biology 2001, the review. Van Troys on the motif. Malinda, Goldstein, Kleinman, FASEB 1997, endothelial crawl. Bock-Marquette, Srivastava, Nature 2004, integrin-linked kinase and a ligation phenotype. Smart, Riley, Nature 2007, epicardial progenitors. Sosne, Experimental Eye Research 2002, alkali-burned cornea. The RGN-259 and RGN-137 programmes, so the clinical-adjacent neighbour stays sized as mixed Phase 2, not as a caption. Carretero on Ac-SDKP, so the tetrapeptide stays a third tube. Hsieh and Chang, if you also opened the BPC-157 vial, so VEGFR2 and FAK stay on that certificate. Pollard’s reviews, so the treadmill stays a cycle with named machines. That's a fortnight of evenings, not a guru. The healing headlines will still be there when you come back, and they will look smaller.

In short. A short stack of named papers covers the identification, the motif, the vessel-cell crawl, the heart, the eye and the separate anti-scarring fragment.

What you should leave with is a topology, not a shopping list. Thymosin β4 is the principal G-actin sequestering peptide, forty-three disordered residues, micromolar, one-to-one with monomer. LKKTETQ is the grip. TB-500 is a research analogue built around that grip, not automatically the 43-mer the Nature papers used. Injury releases the peptide; VEGF, MMP-2 and keratinocyte migration follow on the extracellular literature. Cardiac and corneal phenotypes that matter used full-length Tβ4. Ac-SDKP is a separate N-terminal anti-fibrotic fragment generated by prolyl oligopeptidase. BPC-157 is a gastric 15-mer with a VEGFR2 and FAK story, a different molecule, a folklore pair. The 10 mg cake is lyophilised analogue for the assays that topology demands: HPLC-MS, a pyrene curve, a G/F spin, a scratch with a scrambled ligand. Full-length Tβ4 is a different order if your model is Sosne or Srivastava. The tetrapeptide is a third order if your model is fibrosis. If your experiment needs the analogue, weigh it, confirm it, and name the binding event. If it needs a medicine, this catalogue doesn't sell one.

In short. Leave with a map you can hold: actin buffer, grip motif, lab analogue, injury as a spill, heart and eye as full-protein papers, plus a separate anti-scarring fragment and a different stomach peptide.

Research-use-only. Not for human consumption / not a medicine. The lyophilised TB-500 on this listing is a laboratory analogue, HPLC-characterised at ≥98 percent, labelled for in-vitro work: a pyrene-actin curve, a G/F-actin spin, a scratch whose ligand you've actually named. The physiology in the paragraphs above is public, cited, and older than the vial. Use it to design the experiment you have the controls for, with the chain named, the compartment named, and the time point written down. Read Safer, read Huff, read Bock-Marquette and Sosne, then weigh the cake. We'll sell you the analogue. We won't tell you it is the forty-three-mer a Nature cardiac figure used, or the tetrapeptide an ACE inhibitor raises, or a stack with a gastric 15-mer. Repair, on this node, is a cytoskeletal programme. Programmes run on characterised reagents, on cells whose type you state, on curves rather than captions, and on a willingness to publish the well that didn't close. The crawl is actin. This reserve you can weigh.

In short. The vial is a research chemical for experiments, not a medicine and not food — the biology is public, so weigh it, measure the actin job, and keep the claim the size of the chromatogram.